“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners.
Imagion said that an independent, blinded review by a panel of expert breast cancer radiologists corroborated its previously reported findings that Magsense had the potential to detect tumor cells in lymph nodes by MRI.
The company said that each radiologist ascertained that the Magsense human epidermal growth factor receptor 2 (HER2) imaging agent “produced a change in image contrast and that the contrast in nodes highly suspicious for tumor was distinctly different from the magnetic resonance imaging (MRI) contrast seen in non-involved nodes.”
… continue reading the full column in the link below:
